Floatz logo

236 assets in Ovarian Carcinoma

Therapeutic assets addressing Ovarian Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Mirvetuximab Soravtansine
Ovarian Carcinoma
AstraZenecaP3BBB (76)
Carboplatin
Ovarian Carcinoma
University of WashingtonP3BB (71)
Irinotecan
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2BB (71)
Olaparib
Ovarian Carcinoma
ImunonP4BB (71)
Durvalumab
Ovarian Carcinoma
AGO Research GmbHP2BB (70)
Lenvatinib
Ovarian Carcinoma
University Medical Center GroningenP4BB (70)
Palbociclib
Ovarian Carcinoma
University Medical Center GroningenP4BB (70)
Adriamycin
Ovarian Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.P3BB (69)
Ziv-Aflibercept
Ovarian Carcinoma
National Cancer Institute (NCI)P2BB (69)
Atezolizumab
Ovarian Carcinoma
OHSU Knight Cancer InstituteP3BB (68)
Cis-Diamminedichloroplatinum Ii
Ovarian Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP3BB (67)
Cyclophosphamide
Ovarian Carcinoma
Beijing BiotechP2BB (67)
Nogitecan
Ovarian Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.P3BB (67)
Cabozantinib
Ovarian Carcinoma
M.D. Anderson Cancer CenterP2BB (66)
Capecitabine
Ovarian Carcinoma
OHSU Knight Cancer InstituteP3BB (66)
Catequentinib
Ovarian Carcinoma
Lei LiP3BB (66)
Docetaxel
Ovarian Carcinoma
Case Comprehensive Cancer CenterP3BB (66)
Letrozole
Ovarian Carcinoma
OHSU Knight Cancer InstituteP3BB (66)
Niraparib
Ovarian Carcinoma
ImunonP4BB (66)
Tamoxifen
Ovarian Carcinoma
OHSU Knight Cancer InstituteP3BB (66)
Veliparib
Ovarian Carcinoma
National Cancer Institute (NCI)P2BB (66)
Abemaciclib
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2BB (65)
Belinostat
Ovarian Carcinoma
University of UtahP2BB (65)
Dostarlimab
Ovarian Carcinoma
University of WashingtonP3BB (65)
Trastuzumab
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2BB (65)
Anastrozole
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2BB (64)
Cediranib
Ovarian Carcinoma
National Cancer Institute (NCI)P3BB (64)
Decitabine
Ovarian Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoP2BB (64)
Oxaliplatin
Ovarian Carcinoma
Moscow Regional Oncological DispensaryP3BB (64)
Vinorelbine Ditartrate
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2BB (64)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (63)
Imnn-001
Ovarian Carcinoma
ImunonP3B (63)
Pazopanib
Ovarian Carcinoma
University Medical Center GroningenP4B (63)
Ribociclib
Ovarian Carcinoma
Avenzo Therapeutics, Inc.P2B (63)
Ipilimumab
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (62)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Ovarian Carcinoma
Mayo ClinicP2B (62)
Nivolumab
Ovarian Carcinoma
Instituto do Cancer do Estado de São PauloP3B (62)
Pembrolizumab
Ovarian Carcinoma
Roswell Park Cancer InstituteP3B (62)
Stapuldencel
Ovarian Carcinoma
Peking University Third HospitalP2B (62)
Rucaparib
Ovarian Carcinoma
pharmaand GmbHP3B (61)
Berzosertib
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (60)
Fluorouracilum
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (60)
Fulvestrant
Ovarian Carcinoma
Atavistik Bio, IncP2B (60)
Hydroxychloroquine
Ovarian Carcinoma
Northwestern UniversityP2B (60)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Ovarian Carcinoma
City of Hope Medical CenterP2B (60)
Ny-Eso-1 Peptide Vaccine
Ovarian Carcinoma
Georgetown UniversityP2B (60)
Paclitaxel Lipid Suspension
Ovarian Carcinoma
Jina Pharmaceuticals Inc.P3B (60)
Pertuzumab
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Talazoparib
Ovarian Carcinoma
National Cancer Institute (NCI)P2B (60)
Trastuzumab Emtansine
Ovarian Carcinoma
OHSU Knight Cancer InstituteP2B (60)
Showing 1 to 50 of 236 assets
PreviousPage 1 of 5Next